Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy

被引:0
|
作者
Sun, Qi [1 ,2 ]
Yang, Yuan-Zhong [1 ,2 ]
Yang, Ping [1 ,2 ]
Li, Yong-Hong [1 ,3 ]
Cao, Yun [1 ,2 ]
Chen, Dong [1 ,3 ]
Zhang, Yijun [1 ,2 ]
机构
[1] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Urol, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate cancer; nADT; BCR; Predict; Nomogram; RADICAL PROSTATECTOMY; PTEN LOSS; RISK; CARCINOMA; ADENOCARCINOMA; FLUTAMIDE; OUTCOMES; ACETATE;
D O I
10.1007/s11255-023-03658-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundA predictive model for biochemical recurrence (BCR) of prostate cancer (PCa) after neoadjuvant androgen deprivation therapy (nADT) has not been established. This study was aimed at determining multiparameter variables that could be used to construct a nomogram to predict the post-nADT BCR of PCa.MethodsOverall, 43 radical prostatectomy specimens from PCa patients who had undergone nADT were collected. Multiparameter variables were analyzed by univariate and then multivariate logistic analyses to identify the independent prognostic factors for predicting BCR. The predictive model was established using Lasso regression analysis.ResultsUnivariate logistic analysis revealed six variables, pathology stage; margins; categorization as group A, B, or C; nucleolus grading; percentage of tumor involvement (PTI); and PTEN status were significantly associated with the BCR of PCa (all p < 0.05). Multivariate logistic regression analysis suggested that categorization as group C, severe nucleolus grading, PTI less than or equal to 5%, and PTEN loss were positively correlated with BCR (all p < 0.05). A nomogram comprising the four variables predicting BCR was constructed, and it exhibited good discrimination (AUC: 0.985; specificity: 86.2%; sensitivity: 100%). Calibration plots for the probability of freedom from BCR at 1 and 2 years showed a good match between the prediction by the nomogram.ConclusionsWe constructed and validated a nomogram to predict the risk of BCR in PCa patients after nADT. This nomogram is a complement to the existing risk stratification systems for PCa, which could have marked implications for clinical decision-making for PCa patients after nADT.
引用
收藏
页码:2215 / 2224
页数:10
相关论文
共 50 条
  • [1] Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
    Qi Sun
    Yuan-Zhong Yang
    Ping Yang
    Yong-Hong Li
    Yun Cao
    Dong Chen
    Yijun Zhang
    International Urology and Nephrology, 2023, 55 : 2215 - 2224
  • [2] Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer
    Hennenfent, BR
    BRITISH JOURNAL OF UROLOGY, 1998, 82 (01): : 166 - 166
  • [3] INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER
    Sanchez-Salas, R. E.
    Prapotnich, D.
    Secin, F. P.
    Favaretto, R.
    Flamand, V
    Rozet, F.
    Galiano, M.
    Barret, E.
    Cathelineau, X.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 91 - 92
  • [4] INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER
    Sanchez-Salas, Rafael
    Prapotnich, Dominique
    Secin, Fernando
    Favaretto, Ricardo
    Rozet, Francois
    Flamand, Vincent
    Galiano, Marc
    Cathala, Nathalie
    Mombet, Annick
    Barret, Eric
    Cathelineau, Xavier
    JOURNAL OF UROLOGY, 2011, 185 (04): : E142 - E143
  • [5] Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer
    McKay, Rana R.
    Gray, Kathryn P.
    Hayes, Julia H.
    Bubley, Glenn J.
    Rosenberg, Jonathan E.
    Hussain, Arif
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2015, 121 (15) : 2603 - 2611
  • [6] Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy
    Ghadjar, Pirus
    Aebersold, Daniel M.
    Albrecht, Clemens
    Boehmer, Dirk
    Flentje, Michael
    Ganswindt, Ute
    Hoecht, Stefan
    Hoelscher, Tobias
    Sedlmayer, Felix
    Wenz, Frederik
    Zips, Daniel
    Wiegel, Thomas
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (07) : 619 - 626
  • [7] Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
    C C Parker
    A R Norman
    R A Huddart
    A Horwich
    D P Dearnaley
    British Journal of Cancer, 2002, 86 : 686 - 691
  • [8] Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
    Parker, CC
    Norman, AR
    Huddart, RA
    Horwich, A
    Dearnaley, DP
    BRITISH JOURNAL OF CANCER, 2002, 86 (05) : 686 - 691
  • [9] Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer
    Fu, Alex Z.
    Tsai, Huei-Ting
    Haque, Reina
    Yood, Marianne Ulcickas
    Cassidy-Bushrow, Andrea E.
    Van Den Eeden, Stephen K.
    Keating, Nancy L.
    Smith, Matthew R.
    Zhou, Yingjun
    Aaronson, David S.
    Potosky, Arnold L.
    JOURNAL OF UROLOGY, 2017, 197 (06): : 1448 - 1454
  • [10] A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer
    Spiegel, Daphna Y.
    Hong, Julian C.
    Oyekunle, Taofik
    Waters, Laura
    Lee, W. Robert
    Salama, Joseph K.
    Koontz, Bridget F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (04): : 834 - 842